Researchers from Bochum and Leipzig have successfully used a soil bacterium to specifically produce prodrugs.
The key to this step was a detailed understanding of the metabolisation of indole, a natural compound which first must be activated in microorganisms.
To do this, they needed a monooxygenase, the molecular structure of which has been clarified for the first time. The findings open up possibilities for the biocatalysis of various active pharmaceutical ingredients.
The two teams led by Professor Dirk Tischler from Ruhr University Bochum and Professor Norbert Sträter from Leipzig University reported in the journal Angewandte Chemie International Edition on 10 February 2023.
Indole is a naturally occurring compound, the typical odour of which is known to many people from rapeseed fields. Various microorganisms metabolise this compound, but it must first be activated, which takes place with the help of what is known as indole monooxygenase.
The enzyme can bind to molecular atmospheric oxygen with the involvement of a cofactor and can be used for the selective epoxidation of indole. This creates a highly reactive epoxide, which can then be introduced into the metabolism.
“What makes this class of monooxygenases special is that it has not been possible so far to unravel their molecular structure in combination with substrate and cofactor,” says Dirk Tischler. “We have now finally managed it!”
This opens up the possibility of using these monooxygenases for a more sustainable biocatalysis of active pharmaceutical ingredients, as indole monooxygenases and styrene monooxygenases form a subgroup of what are known as flavoprotein monooxygenases, which can oxygenate double bonds or sulphur atoms in a highly selective manner. Researchers refer to this as epoxidation and sulfoxidation.
Depending on the substrate, both enzyme types can also catalyse what are known as chiral reactions, during which only the desired product is created without any unwanted byproducts.
“This is particularly essential during the manufacture of active pharmaceutical ingredients, as molecules and their unwanted twins can have very different effects,” explains Dirk Tischler. As no byproducts are created and the reactions take place under mild conditions, biocatalysis is considered particularly sustainable.
The researchers were also able to transfer insights into the epoxidation of indole to other compounds, including indene. The latter is structurally very similar to indole.
“If you can selectively epoxidate indene, you open up the path to producing an active ingredient against HIV protease,” says Tischler. “However, up to now, we have lacked the structural and mechanistical details to get an indole monooxygenase to effectively catalyse this reaction.”
In the current work, the research team managed to unravel the structure of the epoxidase subunit IndA1 from the soil bacterium Variovorax paradoxus EPS and dramatically increase the efficiency of epoxidation with specific genetic changes. The wild-type protein only produced 35 per cent pure indene oxide, whereas the mutant generates more than 99 per cent purity.
The 1S,2R-indene oxide produced in this way can be used as a precursor for a HIV protease inhibitor.
“This shows the importance of the molecular understanding of protein structures for biocatalysis and also the possibilities of directed evolution for applied research,” summarises Dirk Tischler.